65
submitted 3 months ago by alyaza@beehaw.org to c/news@beehaw.org

Lenacapavir , sold as Sunlenca by US pharmaceutical giant Gilead, currently costs $42,250 for the first year. The company is being urged to make it available at a thousand times less than that price worldwide.

UNAids said it could “herald a breakthrough for HIV prevention” if the drug was available “rapidly and affordably”.

Given by injection every six months, lenacapavir can prevent infection and suppress HIV in people who are already infected.

In a trial, the drug offered 100% protection to more than 5,000 women in South Africa and Uganda, according to results announced by Gilead last month.

you are viewing a single comment's thread
view the rest of the comments
[-] theangriestbird@beehaw.org 8 points 3 months ago

so much of it is paid with grants anyway, I don’t think pharma companies should keep any profits unless they fund 100% of the r&d for it, which they won’t

This is a strong point. If so much of this R&D is government-funded, then why tf are the drug companies allowed to profit from it? Corporate welfare is America's only real welfare problem.

this post was submitted on 24 Jul 2024
65 points (100.0% liked)

World News

22055 readers
132 users here now

Breaking news from around the world.

News that is American but has an international facet may also be posted here.


Guidelines for submissions:

These guidelines will be enforced on a know-it-when-I-see-it basis.


For US News, see the US News community.


This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 2 years ago
MODERATORS